Company intelligence / Profile preview

Oncosia Scientific

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Oncosia Scientific is a biotechnology company focused on the development of innovative small molecule therapeutics targeting cancer metabolism. The company's lead research program centers on the inhibition of Monocarboxylate Transporter 1 (MCT1), a critical transporter that facilitates the efflux of lactate in glycolytic cancer cells. By blocking MCT1, Oncosia's drug candidates aim to disrupt the metabolic balance of tumor cells, leading to inhibited growth and apoptosis. The company is primarily targeting solid tumors and certain hematological malignancies where MCT1 expression is a key driver of disease progression.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Oncosia Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncosia Scientific.

Explore the full profile